About this trial
Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. Both the kidney damage and growth failure are thought to be due to the accumulation of the amino acid cystine within the cells of the body. The cystine storage later damages other organs besides the kidneys, including the thyroid gland, pancreas, eyes, and muscle.
The drug cysteamine (Cystagon; ProCysBi) is an oral medication given to patients with cystinosis prior to kidney transplantation. The drug works by reducing the level of cystine in the white blood cells and muscle tissue. The drug may also decrease levels of cystine in the kidneys and other tissues.
This study has several goals:
1. Long-term surveillance of cysteamine treated patients. 2. Detection of new non-kidney complications of cystinosis. 3. Maintenance of a patient population for genetic testing (mutational analysis) of the cystinosis gene.\<TAB\>
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Patients with a diagnosis of cystinosis
Trial design
Cohort
Prospective
Treatments tested in this trial
Cysteamine
DrugCystine-depleting agent
Treatment groups
Trial outcomes
Primary outcomes
Serve as a source of knowledge and advice for individual cystinosis patients and for the community at large
Serve as a source of knowledge and advice for individual cystinosis patients and for the community at large
Sponsors and contacts
Click on the lead sponsor to view all of their trials.